289 related articles for article (PubMed ID: 31351252)
1. Perlecan domain I gradients establish stable biomimetic heparin binding growth factor gradients for cell migration in hydrogels.
Hubka KM; Carson DD; Harrington DA; Farach-Carson MC
Acta Biomater; 2019 Oct; 97():385-398. PubMed ID: 31351252
[TBL] [Abstract][Full Text] [Related]
2. Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders.
Farach-Carson MC; Warren CR; Harrington DA; Carson DD
Matrix Biol; 2014 Feb; 34():64-79. PubMed ID: 24001398
[TBL] [Abstract][Full Text] [Related]
3. Injectable perlecan domain 1-hyaluronan microgels potentiate the cartilage repair effect of BMP2 in a murine model of early osteoarthritis.
Srinivasan PP; McCoy SY; Jha AK; Yang W; Jia X; Farach-Carson MC; Kirn-Safran CB
Biomed Mater; 2012 Apr; 7(2):024109. PubMed ID: 22455987
[TBL] [Abstract][Full Text] [Related]
4. Injectable glycosaminoglycan hydrogels for controlled release of human basic fibroblast growth factor.
Cai S; Liu Y; Zheng Shu X; Prestwich GD
Biomaterials; 2005 Oct; 26(30):6054-67. PubMed ID: 15958243
[TBL] [Abstract][Full Text] [Related]
5. Perlecan, A Multi-Functional, Cell-Instructive, Matrix-Stabilizing Proteoglycan With Roles in Tissue Development Has Relevance to Connective Tissue Repair and Regeneration.
Hayes AJ; Farrugia BL; Biose IJ; Bix GJ; Melrose J
Front Cell Dev Biol; 2022; 10():856261. PubMed ID: 35433700
[TBL] [Abstract][Full Text] [Related]
6. Perlecan knockdown in metastatic prostate cancer cells reduces heparin-binding growth factor responses in vitro and tumor growth in vivo.
Savorè C; Zhang C; Muir C; Liu R; Wyrwa J; Shu J; Zhau HE; Chung LW; Carson DD; Farach-Carson MC
Clin Exp Metastasis; 2005; 22(5):377-90. PubMed ID: 16283481
[TBL] [Abstract][Full Text] [Related]
7. A novel peptide sequence in perlecan domain IV supports cell adhesion, spreading and FAK activation.
Farach-Carson MC; Brown AJ; Lynam M; Safran JB; Carson DD
Matrix Biol; 2008 Mar; 27(2):150-60. PubMed ID: 17997086
[TBL] [Abstract][Full Text] [Related]
8. SULF1 suppresses Wnt3A-driven growth of bone metastatic prostate cancer in perlecan-modified 3D cancer-stroma-macrophage triculture models.
Brasil da Costa FH; Lewis MS; Truong A; Carson DD; Farach-Carson MC
PLoS One; 2020; 15(5):e0230354. PubMed ID: 32413029
[TBL] [Abstract][Full Text] [Related]
9. Perlecan and tumor angiogenesis.
Jiang X; Couchman JR
J Histochem Cytochem; 2003 Nov; 51(11):1393-410. PubMed ID: 14566013
[TBL] [Abstract][Full Text] [Related]
10. HIP/RPL29 antagonizes VEGF and FGF2 stimulated angiogenesis by interfering with HS-dependent responses.
D'Souza S; Yang W; Marchetti D; Muir C; Farach-Carson MC; Carson DD
J Cell Biochem; 2008 Dec; 105(5):1183-93. PubMed ID: 18980226
[TBL] [Abstract][Full Text] [Related]
11. Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation.
Castillo GM; Cummings JA; Yang W; Judge ME; Sheardown MJ; Rimvall K; Hansen JB; Snow AD
Diabetes; 1998 Apr; 47(4):612-20. PubMed ID: 9568695
[TBL] [Abstract][Full Text] [Related]
12. Heparan sulfate side chains have a critical role in the inhibitory effects of perlecan on vascular smooth muscle cell response to arterial injury.
Gotha L; Lim SY; Osherov AB; Wolff R; Qiang B; Erlich I; Nili N; Pillarisetti S; Chang YT; Tran PK; Tryggvason K; Hedin U; Tran-Lundmark K; Advani SL; Gilbert RE; Strauss BH
Am J Physiol Heart Circ Physiol; 2014 Aug; 307(3):H337-45. PubMed ID: 24858854
[TBL] [Abstract][Full Text] [Related]
13. Coating electrospun collagen and gelatin fibers with perlecan domain I for increased growth factor binding.
Casper CL; Yang W; Farach-Carson MC; Rabolt JF
Biomacromolecules; 2007 Apr; 8(4):1116-23. PubMed ID: 17326680
[TBL] [Abstract][Full Text] [Related]
14. Matrilysin/MMP-7 Cleavage of Perlecan/HSPG2 Complexed with Semaphorin 3A Supports FAK-Mediated Stromal Invasion by Prostate Cancer Cells.
Grindel BJ; Martinez JR; Tellman TV; Harrington DA; Zafar H; Nakhleh L; Chung LW; Farach-Carson MC
Sci Rep; 2018 May; 8(1):7262. PubMed ID: 29740048
[TBL] [Abstract][Full Text] [Related]
15. Elevated hypertrophy, growth plate maturation, glycosaminoglycan deposition, and exostosis formation in the
Shu CC; Smith SM; Little CB; Melrose J
Biochem J; 2019 Jan; 476(2):225-243. PubMed ID: 30563944
[TBL] [Abstract][Full Text] [Related]
16. Perlecan domain I promotes fibroblast growth factor 2 delivery in collagen I fibril scaffolds.
Yang WD; Gomes RR; Alicknavitch M; Farach-Carson MC; Carson DD
Tissue Eng; 2005; 11(1-2):76-89. PubMed ID: 15738663
[TBL] [Abstract][Full Text] [Related]
17. Covalently immobilized gradients of bFGF on hydrogel scaffolds for directed cell migration.
DeLong SA; Moon JJ; West JL
Biomaterials; 2005 Jun; 26(16):3227-34. PubMed ID: 15603817
[TBL] [Abstract][Full Text] [Related]
18. Syndecan-3 and perlecan are differentially expressed by progenitors and mature oligodendrocytes and accumulate in the extracellular matrix.
Winkler S; Stahl RC; Carey DJ; Bansal R
J Neurosci Res; 2002 Aug; 69(4):477-87. PubMed ID: 12210841
[TBL] [Abstract][Full Text] [Related]
19. The in vitro effects of macrophages on the osteogenic capabilities of MC3T3-E1 cells encapsulated in a biomimetic poly(ethylene glycol) hydrogel.
Saleh LS; Carles-Carner M; Bryant SJ
Acta Biomater; 2018 Apr; 71():37-48. PubMed ID: 29505890
[TBL] [Abstract][Full Text] [Related]
20. Epidermal transformation leads to increased perlecan synthesis with heparin-binding-growth-factor affinity.
Tapanadechopone P; Tumova S; Jiang X; Couchman JR
Biochem J; 2001 Apr; 355(Pt 2):517-27. PubMed ID: 11284741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
